VGXI, a plasmid DNA contract manufacturing organization, unveiled the grand opening of a facility expansion which includes flexible scale plasmid DNA manufacturing space as well as purpose-built GMP production areas for RNA synthesis.   Increasing the company’s footprint by 17% and cGMP manufacturing space by over 70%, this expansion was initiated in anticipation of the recently finalized license and partnership with Houston Methodist Research Institute (HMRI). Under the partnership, technolog...